Global ovarian cancer health disparities

Ganna Chornokur, Ernest K. Amankwah, Joellen M. Schildkraut, Catherine M. Phelan

Research output: Contribution to journalArticle

Abstract

Objective The objective of this article is to broadly review the scientific literature and summarize the most up-to-date findings on ovarian cancer health disparities worldwide and in the United States (U.S.). Methods The present literature on disparities in ovarian cancer was reviewed. Original research and relevant review articles were included. Results Ovarian cancer health disparities exist worldwide and in the U.S. Ovarian cancer disproportionately affect African American women at all stages of the disease, from presentation through treatment, and ultimately increased mortality and decreased survival, compared to non-Hispanic White women. Increased mortality is likely to be explained by unequal access to care and non-standard treatment regimens frequently administered to African American women, but may also be attributed to genetic susceptibility, acquired co-morbid conditions and increased frequency of modifiable risk factors, albeit to substantially lesser extent. Unequal access to care is, in turn, largely a consequence of lower socioeconomic status and lack of private health insurance coverage among the African American population. Conclusions Our findings suggest the need for policy changes aimed at facilitating equal access to quality medical care. At the same time, further research is necessary to fully resolve racial disparities in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)258-264
Number of pages7
JournalGynecologic Oncology
Volume129
Issue number1
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Ovarian Neoplasms
African Americans
Health
Insurance Coverage
Mortality
Quality of Health Care
Genetic Predisposition to Disease
Health Insurance
Standard of Care
Research
Social Class
Survival
Therapeutics
Population

Keywords

  • Health disparities
  • Ovarian cancer
  • Race

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Chornokur, G., Amankwah, E. K., Schildkraut, J. M., & Phelan, C. M. (2013). Global ovarian cancer health disparities. Gynecologic Oncology, 129(1), 258-264. https://doi.org/10.1016/j.ygyno.2012.12.016

Global ovarian cancer health disparities. / Chornokur, Ganna; Amankwah, Ernest K.; Schildkraut, Joellen M.; Phelan, Catherine M.

In: Gynecologic Oncology, Vol. 129, No. 1, 04.2013, p. 258-264.

Research output: Contribution to journalArticle

Chornokur, G, Amankwah, EK, Schildkraut, JM & Phelan, CM 2013, 'Global ovarian cancer health disparities', Gynecologic Oncology, vol. 129, no. 1, pp. 258-264. https://doi.org/10.1016/j.ygyno.2012.12.016
Chornokur, Ganna ; Amankwah, Ernest K. ; Schildkraut, Joellen M. ; Phelan, Catherine M. / Global ovarian cancer health disparities. In: Gynecologic Oncology. 2013 ; Vol. 129, No. 1. pp. 258-264.
@article{918f22b29ff14d1cb156d7de1848a810,
title = "Global ovarian cancer health disparities",
abstract = "Objective The objective of this article is to broadly review the scientific literature and summarize the most up-to-date findings on ovarian cancer health disparities worldwide and in the United States (U.S.). Methods The present literature on disparities in ovarian cancer was reviewed. Original research and relevant review articles were included. Results Ovarian cancer health disparities exist worldwide and in the U.S. Ovarian cancer disproportionately affect African American women at all stages of the disease, from presentation through treatment, and ultimately increased mortality and decreased survival, compared to non-Hispanic White women. Increased mortality is likely to be explained by unequal access to care and non-standard treatment regimens frequently administered to African American women, but may also be attributed to genetic susceptibility, acquired co-morbid conditions and increased frequency of modifiable risk factors, albeit to substantially lesser extent. Unequal access to care is, in turn, largely a consequence of lower socioeconomic status and lack of private health insurance coverage among the African American population. Conclusions Our findings suggest the need for policy changes aimed at facilitating equal access to quality medical care. At the same time, further research is necessary to fully resolve racial disparities in ovarian cancer.",
keywords = "Health disparities, Ovarian cancer, Race",
author = "Ganna Chornokur and Amankwah, {Ernest K.} and Schildkraut, {Joellen M.} and Phelan, {Catherine M.}",
year = "2013",
month = "4",
doi = "10.1016/j.ygyno.2012.12.016",
language = "English (US)",
volume = "129",
pages = "258--264",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Global ovarian cancer health disparities

AU - Chornokur, Ganna

AU - Amankwah, Ernest K.

AU - Schildkraut, Joellen M.

AU - Phelan, Catherine M.

PY - 2013/4

Y1 - 2013/4

N2 - Objective The objective of this article is to broadly review the scientific literature and summarize the most up-to-date findings on ovarian cancer health disparities worldwide and in the United States (U.S.). Methods The present literature on disparities in ovarian cancer was reviewed. Original research and relevant review articles were included. Results Ovarian cancer health disparities exist worldwide and in the U.S. Ovarian cancer disproportionately affect African American women at all stages of the disease, from presentation through treatment, and ultimately increased mortality and decreased survival, compared to non-Hispanic White women. Increased mortality is likely to be explained by unequal access to care and non-standard treatment regimens frequently administered to African American women, but may also be attributed to genetic susceptibility, acquired co-morbid conditions and increased frequency of modifiable risk factors, albeit to substantially lesser extent. Unequal access to care is, in turn, largely a consequence of lower socioeconomic status and lack of private health insurance coverage among the African American population. Conclusions Our findings suggest the need for policy changes aimed at facilitating equal access to quality medical care. At the same time, further research is necessary to fully resolve racial disparities in ovarian cancer.

AB - Objective The objective of this article is to broadly review the scientific literature and summarize the most up-to-date findings on ovarian cancer health disparities worldwide and in the United States (U.S.). Methods The present literature on disparities in ovarian cancer was reviewed. Original research and relevant review articles were included. Results Ovarian cancer health disparities exist worldwide and in the U.S. Ovarian cancer disproportionately affect African American women at all stages of the disease, from presentation through treatment, and ultimately increased mortality and decreased survival, compared to non-Hispanic White women. Increased mortality is likely to be explained by unequal access to care and non-standard treatment regimens frequently administered to African American women, but may also be attributed to genetic susceptibility, acquired co-morbid conditions and increased frequency of modifiable risk factors, albeit to substantially lesser extent. Unequal access to care is, in turn, largely a consequence of lower socioeconomic status and lack of private health insurance coverage among the African American population. Conclusions Our findings suggest the need for policy changes aimed at facilitating equal access to quality medical care. At the same time, further research is necessary to fully resolve racial disparities in ovarian cancer.

KW - Health disparities

KW - Ovarian cancer

KW - Race

UR - http://www.scopus.com/inward/record.url?scp=84875433896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875433896&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2012.12.016

DO - 10.1016/j.ygyno.2012.12.016

M3 - Article

C2 - 23266352

AN - SCOPUS:84875433896

VL - 129

SP - 258

EP - 264

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -